Back to News
Market Impact: 0.4
Bayer: FDA Approves Kerendia To Treat Chronic Kidney Disease Associated With Type 1 Diabetes
Source: Nasdaq
Healthcare & BiotechProduct LaunchesRegulation & Legislation
The FDA approved Bayer's Kerendia (finerenone) for adults with chronic kidney disease associated with type 1 diabetes. The decision marks Kerendia's third approved U.S. indication, expanding the drug's addressable patient population and providing a positive incremental growth catalyst for Bayer's pharmaceuticals business.
AllMind Terminal
AI-powered research, real-time alerts, and portfolio analytics for institutional investors.
Request TrialMarket Sentiment
Overall Sentiment
moderately positive
Sentiment Score
0.55
Ticker Sentiment
BAYN0.80
More News
- Bitcoin pinned at $78k after October losses; Binance resumes withdrawals
- Amgen (AMGN) Bets on MariTide to Crack $120 Billion Obesity Market
- BTIG cuts Acumen Pharmaceuticals stock price target to $1 on trial results
- Jefferies raises West Pharmaceutical stock price target on HVP growth
- Wells Fargo raises Abbvie stock price target to $340 on pipeline
- Boris Vujčić: Integrated, open and resilient: Europe’s strengths in a fragmenting world